Scientists watched something remarkable unfold in a laboratory tank: kidneys aging decades in just a few months. And they found a drug already in widespread use that seemed to slow it down.
The African turquoise killifish lives its entire life in four to six months—one of nature's fastest-aging vertebrates. In that compressed timeline, its kidneys develop the same wear-and-tear patterns seen in aging humans: lost blood vessels, damaged filtration barriers, inflammation, struggling energy production. Which makes it an almost perfect natural experiment for studying how organs decline and what might stop it.
An international team of researchers from MDI Biological Laboratory, Hannover Medical School, and Colby College used this biological speedrun to test SGLT2 inhibitors—drugs already prescribed to millions of people with diabetes and heart disease. The results, published in Kidney International, showed something striking: fish treated with these drugs maintained healthier kidneys as they aged, with denser capillary networks, stronger filtration barriers, and more stable energy production in their cells.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxWhy This Matters Beyond the Lab
SGLT2 inhibitors have been clinically proven to protect both kidneys and hearts, but the why has been fuzzy. Doctors knew they did more than just control blood sugar—the protective effects were too large to explain by that mechanism alone. This study illuminates the missing piece.
As untreated killifish aged, their kidneys lost capillaries in a process called vascular rarefaction. With fewer blood vessels delivering oxygen and nutrients, kidney cells shifted to less efficient energy production pathways. The drug-treated fish didn't experience this decline. Their kidneys kept their capillary networks intact and maintained gene activity patterns that resembled younger animals.
"What impressed me most was how a seemingly simple drug influences so many interconnected systems within the kidney," said Anastasia Paulmann, the study's lead researcher, who established the killifish colony specifically for this work. "From blood vessels and energy metabolism to inflammation and overall function."
This matters because kidney disease affects roughly one in seven American adults, often silently. Once damage is advanced, options narrow. A drug that actually slows the aging process—rather than just managing symptoms—could reshape how we think about kidney protection.
What Comes Next
The research team is already planning follow-up studies to test whether SGLT2 inhibitors can repair kidneys after age-related damage has already occurred, and how timing and duration of treatment shape long-term outcomes. The killifish model compresses what would take years of mouse studies into months, creating a faster pipeline for testing which therapies work before they move into human trials.
This is the practical promise of the work: a small fish living at high speed, helping researchers understand whether the drugs we already have might do more than we realized.
